S16 Ep8: ASCO GU 2026 Preview

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium, noting presentations to watch at sessions on prostate cancer, bladder cancer, and renal cell carcinoma (RCC).For prostate cancer, the experts revealed that they're looking forward to seeing updated results from the phase 3 PEACE-3 trial (NCT02194842) of enzalutamide (Xtandi) plus radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC), noting that bone-protecting agents are mandatory for patients receiving radium-223. They also pointed to overall survival data from the phase 2 BRCAAway trial (NCT03012321) of abiraterone (Zytiga) plus prednisone and olaparib (Lynparza) for patients with mCRPC harboring BRCA or ATM alterations. Additionally, they spotlighted the phase 3 PEACE 2 trial (NCT01952223), which explores moving chemotherapy into the localized prostate cancer setting.Regarding bladder cancer, they identified the phase 3 KEYNOTE-B15 trial (NCT04700124) as a potentially practice-changing trial evaluating perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in cisplatin-eligible patients with muscle-invasive bladder cancer. They also noted that circulating tumor DNA data are a significant trend, appearing in several clinical trials to guide response-adapted management.For RCC, the hosts highlighted the phase 3 LITESPARK-011 (NCT04586231) and LITESPARK-022 (NCT05239728) trials, which are evaluating the HIF-2α inhibitor belzutifan (Welireg) in different RCC populations. They also emphasized the importance of the CLIMATE study (ACTRN12622000247774) for detecting residual disease in patients with testicular cancer.